(Q34350209)

1 August 2017

title

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia (English)

1 reference

1 August 2017

1 reference

E H Estey

1

1 reference

1 August 2017

publication date

12 June 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

27

1 reference

1 August 2017

issue

9

1 reference

1 August 2017

page(s)

1803-1812

1 reference

Cancer epigenetics reaches mainstream oncology

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Revised international prognostic scoring system for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

A prognostic score for patients with lower risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Rac GTPases play multiple roles in erythropoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

What is better for older patients with acute myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Genomic impact of transient low-dose decitabine treatment on primary AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Block of red blood cell maturation in acute erythroid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

7 January 2021

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

7 January 2021

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

7 January 2021

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

7 January 2021

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

7 January 2021

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

7 January 2021

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

7 January 2021

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.173

7 January 2021

Identifiers

DOI

10.1038/LEU.2013.173

1 reference

Dimensions Publication ID

1 August 2017

1047612708

0 references

1 reference